Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - cefaclor monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - cefaclor monohydrate -

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - cefaclor monohydrate 27.8 mg/ml equivalent to cefaclor 25 mg/ml;   - granules for oral suspension - 125 mg/5ml - active: cefaclor monohydrate 27.8 mg/ml equivalent to cefaclor 25 mg/ml   excipient: allura red ac citric acid colloidal silicon dioxide simeticone sodium benzoate sodium citrate dihydrate strawberry flavour 052311 ap0551 sucrose xanthan gum - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated micro-organisms: lower respiratory infections, including pneumonia caused by s. pneumoniae, h. influenzae (including both ampicillin-sensitive and ampicillin-resistant strains), and s. pyogenes (group a beta- haemolytic streptococci), m.catarrhalis, acute bronchitis, and acute exacerbations of chronic bronchitis. upper respiratory infections, including pharyngitis and tonsillitis caused by s. pyogenes (group a beta-haemolytic streptococci) and m. catarrhalis. otitis media caused by s. pneumoniae, h. influenzae (including both ampicillin-sensitive and ampicillin-resistant strains) staphylococci, and s. pyogenes (group a beta-haemolytic streptococci), and m. catarrhalis. skin and soft-tissue infections caused by staphylococcus aureus (including ?-lactamase producing strains), s. pyogenes (group a beta-haemolytic streptococci) and staphylococcus epidermidis (including ?-lactamase produc

United States - English - NLM (National Library of Medicine)

jazeera pharmaceutical - cefaclor (unii: 69k7k19h4l) (cefaclor anhydrous - unii:3z6fs3ik0k) - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: otitis media caused by streptococcus pneumoniae , haemophilus influenzae , staphylococci, and streptococcus pyogenes   lower respiratory tract infections , including pneumonia caused by streptococcus pneumoniae , haemophilus influenzae, and streptococcus pyogenes   pharyngitis and tonsillitis , caused by streptococcus pyogenes   note : penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. urinary tract infections , including pyelonephritis and cystitis, caused by escherichia coli, proteus mirabilis, klebsiella spp., and coagulase-negative staphylococci skin

United States - English - NLM (National Library of Medicine)

hikma pharmaceutical - cefaclor (unii: 69k7k19h4l) (cefaclor anhydrous - unii:3z6fs3ik0k) - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: otitis media caused by streptococcus pneumoniae , haemophilus influenzae , staphylococci, and streptococcus pyogenes lower respiratory tract infections , including pneumonia caused by streptococcus pneumoniae , haemophilus influenzae , and streptococcus pyogenes pharyngitis and tonsillitis , caused by streptococcus pyogenes note: penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. urinary tract infections , including pyelonephritis and cystitis, caused by escherichia coli , proteus mirabilis , klebsiella spp., and coagulase-negative staphylococci skin an

United States - English - NLM (National Library of Medicine)

a-s medication solutions - cefaclor (unii: 69k7k19h4l) (cefaclor anhydrous - unii:3z6fs3ik0k) - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: otitis media caused by streptococcus pneumoniae, haemophilus influenzae, staphylococci, and streptococcus pyogenes note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. lower respiratory tract infections, including pneumonia, caused by streptococcus pneumoniae, haemophilus influenzae, and streptococcus pyogenes note: β-lactamase-negative, ampicillin-resistant (blnar) strains of haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some blnar strains. pharyngitis and tonsillitis, caused by streptococcus pyogenes note: penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. urinary tract infections, including pyelonephritis and cystitis, caused by escherichia coli, proteus mirabilis, klebsiella spp., and coagulase-negative staphylococci skin and skin structure infections caused by staphylococcus aureus and streptococcus pyogenes appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor. to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor capsule and other antibacterial drugs, cefaclor capsule should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - cefaclor monohydrate -

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - cefaclor monohydrate 262.3mg equivalent to cefaclor 250 mg; cefaclor monohydrate 262.3mg equivalent to cefaclor 250 mg - capsule - 250 mg - active: cefaclor monohydrate 262.3mg equivalent to cefaclor 250 mg excipient: croscarmellose sodium dimeticone gelatin iron oxide red magnesium stearate titanium dioxide active: cefaclor monohydrate 262.3mg equivalent to cefaclor 250 mg excipient: croscarmellose sodium dimeticone gelatin iron oxide red magnesium stearate titanium dioxide

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - cefaclor monohydrate 524.7mg equivalent to cefaclor 500 mg - capsule - 500 mg - active: cefaclor monohydrate 524.7mg equivalent to cefaclor 500 mg excipient: croscarmellose sodium dimeticone gelatin iron oxide red magnesium stearate titanium dioxide

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - cefaclor monohydrate, quantity: 392.3 mg (equivalent: cefaclor, qty 375 mg) - tablet, modified release - excipient ingredients: mannitol; hypromellose; hyprolose; methacrylic acid copolymer; stearic acid; magnesium stearate; propylene glycol; purified talc; colour - karlor cd is indicated for the treatment of the following types of infections caused by susceptible organisms, in adults and children aged 12 years or older: acute bronchitis and acute exacerbations of chronic bronchitis; upper respiratory infections, including phryngitis, tonsillitis and acute bacterial sinusitis; community-acquired pneumonia of mild to moderate severity (excluding atypical pneumonia); symptomatic lower urinary tact infections, including cystitis; skin and skin structure infections. note: 1. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. karlor cd is generally effective in the eradication of streptococci from the oropharynx; however, substantial data establishing the efficacy of karlor cd in the subsequent prevention of rheumatic fever are not available. 2. bacteriological studies to determine the causative organism and its susceptibility to cefaclor should be performed. therapy may be started